Author: Esperion Therapeutics, Inc.

– Reports $156 to $160 Million in Preliminary* Full-Year 2025 U.S. Net Product Sales, a 35% to 38% Increase Compared With Full-Year 2024 – –Total Preliminary* Revenue of $400 to $408 million, a 20% to 23% Increase Compared With Full-Year 2024, and ~55% to 59% Increase Excluding One-Time Milestones – – Cash and Cash Equivalents of Approximately $168 Million* at Year-End 2025 – – Q4 Retail Prescription Equivalents Grew 34% Y/Y and 11.3% Q/Q – – Expects Operating Expenses of Between $210 Million anRead More

Read More

When I noticed Elif Istanbulluoblu wasn’t in the starting lineup I took to social media to see if there was any word on where she was [sick] so I missed watching the first 45 seconds of the game. Had I known those 45 seconds were last time Pitt was still in the game I might’ve […]Read More

Read More